Supernus Pharmaceuticals, Inc.
) presented data on both its epilepsy drugs - Trokendi XR and
Oxtellar XR, at the American Epilepsy Society (AES) meeting.
Supernus launched its antiepileptic drug, Oxtellar XR, in the
U.S in Feb 2013. During the double-blind PROSPER study on
Oxtellar XR, seizure control was maintained. In addition, seizure
control further improved during the long term open-label
extension when dosages could be optimized. Further, Oxtellar XR
was very well tolerated during long-term maintenance therapy.
Growth in the Oxtellar XR prescriber base has been phenomenal
in the third quarter of 2013, totaling 7,596, up from 3,648 in
the second quarter. Since its launch, more than 1,600 target
physicians have prescribed Oxtellar XR.
Supernus launched Trokendi XR in the third quarter of 2013.
93% of patients preferred Trokendi XR when switched from twice
daily immediate release Topamax. Likewise, 92% of epileptic
patients expect Trokendi XR to deliver better results. Trokendi
XR (once daily) was revealed as bioequivalent to Topamax (twice)
in a head to head study.
With Trokendi XR there is a convenience of taking a dose of
Topamax (once) without increasing the risks of missed, delayed,
or doubled doses. In elder patients, dosage recommendations for
Trokendi XR are similar to that of immediate release Topamax.
By Nov 1, 2013, 4,711 prescriptions were reported by IMS for
Trokendi XR. To aid the launch of Trokendi XR, Supernus increased
its sales force by 15 sales representatives. Additional sales
force expansion is expected shortly.
Trokendi XR and Oxtellar XR are the only marketed products at
Supernus. This additional data on the drugs was encouraging.
Supenus currently carries a Zacks Rank #2 (Buy). Some
better-ranked stocks include
Aeterna Zentaris Inc.
Jazz Pharmaceuticals plc
), each carrying a Zacks Rank #1 (Strong Buy).
AETERNA ZENTARS (AEZS): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SUPERNUS PHARMA (SUPN): Free Stock Analysis
To read this article on Zacks.com click here.